Abstract:Background: Pathological cardiac fibrosis and hypertrophy, the common features of left ventricular remodeling, often progress to heart failure. Forkhead box transcription factor P1 (Foxp1) in endothelial cells (ECs) has been shown to play an important role in heart development. However, the effect of EC-Foxp1 on pathological cardiac remodeling has not been well clarified. This study aims to determine the role of EC-Foxp1 in pathological cardiac remodeling and the underlying mechanisms. Methods: Foxp1 EC-specific loss-of-function and gain-of-function mice were generated, and an angiotensin II infusion or a transverse aortic constriction operation mouse model was used to study the cardiac remodeling mechanisms. Foxp1 downstream target gene transforming growth factor-beta 1 (TGF-beta 1) was confirmed by chromatin immunoprecipitation and luciferase assays. Finally, the effects of TGF-beta 1 blockade on EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes were further confirmed by pharmacological inhibition, more specifically by RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Results: Foxp1 expression is significantly downregulated in cardiac ECs during angiotensin II-induced cardiac remodeling. EC-Foxp1 deletion results in severe cardiac remodeling, including more cardiac fibrosis with myofibroblast formation and extracellular matrix protein production, as well as decompensated cardiac hypertrophy and further exacerbation of cardiac dysfunction on angiotensin II infusion or transverse aortic constriction operation. In contrast, EC-Foxp1 gain of function protects against pathological cardiac remodeling and improves cardiac dysfunction. TGF-beta 1 signals are identified as Foxp1 direct target genes, and EC-Foxp1 deletion upregulates TGF-beta 1 signals to promote myofibroblast formation through fibroblast proliferation and transformation, resulting in severe cardiac fibrosis. Moreover, EC-Foxp1 deletion enhances TGF-beta 1-promoted endothelin-1 expression, which significantly increases cardiomyocyte size and reactivates cardiac fetal genes, leading to pathological cardiac hypertrophy. Correspondingly, these EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes and cardiac dysfunction are normalized by the blockade of TGF-beta 1 signals through pharmacological inhibition and RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Conclusions: EC-Foxp1 regulates the TGF-beta 1-endothelin-1 pathway to control pathological cardiac fibrosis and hypertrophy, resulting in cardiac dysfunction. Therefore, targeting the EC-Foxp1-TGF-beta 1-endothelin-1 pathway might provide a future novel therapy for heart failure.

Knockout of Trpa1 accelerates age-related cardiac fibrosis and dysfunction

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

GW28-e0561 Inhibition of TRPA1 Ameliorates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis in Mice

TRPA1 Deficiency Attenuates Cardiac Fibrosis Via Regulating GRK5/NFAT Signaling in Diabetic Rats

Abstract 14642: Cardiac-specific Transgenic Inhibition of NF-kB Attenuates Apoptosis and Remodeling in the Aging Heart

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice

Age-Associated Impairment in Tnf-Alpha Cardioprotection from Myocardial Infarction

Ablation of toll-like receptor 4 attenuates aging-induced myocardial remodeling and contractile dysfunction through NCoRI-HDAC1-mediated regulation of autophagy.

Exacerbated cardiac fibrosis induced by β-adrenergic activation in old mice due to decreased AMPK activity.

Cardiomyocyte-specific Deletion of Endothelin Receptor A Rescues Aging-Associated Cardiac Hypertrophy and Contractile Dysfunction: Role of Autophagy

Cardiomyocyte-specific Deletion of Endothelin Receptor A (ETA) Obliterates Cardiac Aging Through Regulation of Mitophagy and Ferroptosis.

TRPV4 increases cardiomyocyte calcium cycling and contractility yet contributes to damage in the aged heart following hypoosmotic stress

Cathepsin K knockout alleviates aging-induced cardiac dysfunction.

Sex-dependent deterioration of cardiac function and molecular alterations in age- and disease-associated RAGE overexpression

Early cardiac aging linked to impaired stress-resistance and transcriptional control of stress response, quality control and mitochondrial pathways

AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction.

Double knockout of Akt2 and AMPK predisposes cardiac aging without affecting lifespan: Role of autophagy and mitophagy

The role of transient receptor potential ankyrin 1 in age-related endothelial dysfunction.

Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy

Hyperactive mTORC1/4EBP1 Signaling Dysregulates Proteostasis and Accelerates Cardiac Aging.